Erbitux approved for head and neck cancers

The FDA has approved ImClone's Erbitux for head and neck cancer, the first new therapy for those indications in almost half a century. "This is the first drug approved for head and neck cancer that has shown a survival benefit in this population," the FDA said. The approval came for head and neck cancer that couldn't be removed by surgery. Merck, which markets the therapy in Europe, said last week that a European drug committee issued a favorable opinion of Erbitux for head and neck cancer. Erbitux was originally approved for colorectal cancer.

- read this report from for more information

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.